Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD

• Status: Completed
• Trial end date: 2020-03-30
• Target enrollment: 0
• Participant gender: All

Summary

This work will assess the prevalence in hard-to-treat ADHD of the ineffectiveness of the anesthetic Lidocaine.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PhenoSolve, LLC
• Collaborators: Boston Clinical Trials; NeurAbilities (formerly CRCNJ)
• Treatments: Lidocaine

Criteria

Inclusion Criteria: ADHD

Exclusion Criteria for both arms:

1. known adverse reactions to lidocaine

2. epilepsy, IQ <80, severe head trauma, birth weight <2270 grams, and severe autism;

3. treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers;

4. generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness);

5. mouth sores;

6. Ehlers Danlos syndrome, and

7. red hair.